Yi Lu

Ms. Yi Lu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2026 in Marine Drugs
Verified
Journal Article
Open access
PDF file
YLYong Liu
Yong Liu
YLYi Lu
Yi Lu
MSMeiling Su
Meiling Su
HBHe Bai
He Bai
JWJiahua Wang
Jiahua Wang
MNMuhammad Zohaib Nawaz
Muhammad Zohaib Nawaz
Marine natural products can show biological activity while remaining difficult to identify, reproduce, or obtain in sufficient quantity. This critical narrative review examines that mismatch and proposes a linked record for each exact chemical entity-indication pair. The documented evaluation stage (E1–E4) records computational, in vitro, animal, or human evaluation; the production/access stage (S1–S5) records physical access, an executed laboratory route, controlled pilot production, good manufacturing practice (GMP) clinical manufacture, or established commercial manufacture. Neither coordinate measures therapeutic merit, evidence strength, sustainability, or probability of success. Computational contribution (C), study quality, evidence direction, identity status, regulatory status, and scenario-specific supply adequacy remain separate. Seven purposively selected case lineages illustrate parent-derivative distinctions, computation-linked isolation, untested nominations, later synthesis, and unresolved assay-material identity. Cynthichlorine illustrates incomplete production reporting, while incompletely matched meridianin mixtures remain outside the joint matrix. A calculation comparing reported (+)-aeroplysinin-1 output with an explicitly defined assay requirement makes the supply question concrete without claiming that the scenario was performed. Borderline coding examples and stricter category rules support future independent application. No inter-rater assessment or prospective decision-impact study was performed; the proposal remains unvalidated. Its intended contribution is an auditable connection between evidence, material, and the next proposed experiment, rather than a readiness score.

22 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
YLYong Liu
Yong Liu
YLYi Lu
Yi Lu
MSMeiling Su
Meiling Su
HBHe Bai
He Bai
JWJiahua Wang
Jiahua Wang
MNMuhammad Zohaib Nawaz
Muhammad Zohaib Nawaz
Marine invertebrates and their microbial partners provide distinctive chemical scaffolds, but computational prioritization alone can overstate translational progress when experimental support and material supply remain limited. This critical narrative review proposes a linked-record framework for evaluating exact entity-indication pairs on two independent axes: therapeutic-evaluation stage (E1, in silico, to E4, human intervention) and production readiness (S1, discovery access, to S4, GMP or commercial manufacture). E records the highest stage documented in the reviewed sources, not evidence strength or therapeutic success. Computational contribution, evidence direction, study quality, provenance, and scenario-specific supply adequacy remain separate attributes; E and S are not combined into a composite score. Contrasting lineages involving halichondrin B and eribulin, (+)-aeroplysinin-1, a sea-star steroid, acanthomanzamine C, cynthichlorine, gukulenin A, and meridianin mixtures illustrate how uncertain chronology, test-article mismatch, incomplete validation, and poorly characterized production routes affect interpretation. A worked mass balance distinguishes physical access from the amount required for a defined experiment. Supply-by-design therefore integrates identity, route feasibility, demand, ecological constraints, and access obligations at nomination. The framework is preliminary and requires independent reliability and prospective utility testing.